WT1, PRAME, and PR3 mRNA Expression in Acute Myeloid Leukemia (AML).

Area of Science:

• Oncology
• Immunology
• Molecular Biology

Background:

• Tumor-associated antigens (TAAs) are potential targets for cancer immunotherapy and monitoring.
• Understanding TAA expression in acute myeloid leukemia (AML) is crucial for developing effective treatments.

Purpose of the Study:

• To analyze the expression levels of PRAME, WT1, and PR3 in myeloid blasts from AML patients.
• To correlate TAA expression with AML subtypes, disease state, and disease course.
• To inform the design of TAA-based immunotherapy strategies.

Main Methods:

• Real-time quantitative polymerase chain reaction (qPCR) was used to measure TAA RNA expression levels.
• Expression data were analyzed in relation to patient diagnosis, AML subtypes (FAB classification), cytogenetic risk, and disease progression.
• TAA expression levels were adjusted for blast percentage for comparative analysis during the disease course.

Main Results:

• High frequencies of PRAME (87%), WT1 (81%), and PR3 (55%) overexpression were observed at initial diagnosis.
• PRAME and WT1 co-expression was the most frequent combination (70%).
• Elevated PRAME expression correlated with FAB subtype M5, unfavorable cytogenetics, and secondary AML.
• TAA expression showed a trend towards higher levels in peripheral blood blasts compared to bone marrow.

Conclusions:

• PRAME, WT1, and PR3 are frequently overexpressed in AML myeloid blasts.
• TAA expression patterns vary with AML subtype and disease progression.
• Cancer immunotherapy vaccine strategies should consider a range of TAA peptides to address diverse expression profiles during disease evolution.